Purpose This study investigated pathological complete response (pCR) according to androgen receptor (AR) in breast cancer patients undergoing neoadjuvant chemotherapy and estimated the relationship between AR expression and clinicopathological factors.
Materials and Methods We identified 624 breast cancer patients who underwent surgery after neoadjuvant chemotherapy at the National Cancer Center in Goyang, Korea from April 2016 to October 2019. We retrospectively collected the clinicopathologic information and AR expression results and analyzed the data according to cancer stage, hormonal receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, tumor subtype, and pCR.
Results Among the 624 breast cancer patients, 529 (84.8%) were AR-positive (AR+) patients and 95 (15.2%) were AR-negative (AR–) patients. AR+ patients showed more estrogen receptor (ER) positivity, progesterone receptor (PR) positivity, HER2-positivity, and HR-positive and HER2-negative (HR+/HER2–) subtype. The rate of pCR was 31.4% (196/624). AR– patients had a significantly higher rate of pCR than AR+ patients (AR– 43.2% vs. AR+ 29.3%, p=0.007). The tumor factors associated with pCR were early stage, histologic grade 3, ER-negative, PR-negative, AR-negative, HER2-positive, and high Ki-67 values. In univariable analysis, AR+ significantly decreased the state of pCR (odds ratio, 0.546; 95% confidence interval, 0.349 to 0.853; p=0.008). According to tumor subtype, AR– tumor showed higher pCR rate in HR+/HER2– subtype (AR– 28.6% vs. AR+ 7.3%, p=0.022).
Conclusion AR expression is predominant in the HR+/HER2– subtype. AR– is significantly associated with the pCR rate in breast cancer patients, especially within HR+/HER2– subtype. When determining neoadjuvant chemotherapy for the HR+/HER2– subtype, AR expression can be considered as a pCR predictive marker.
Citations
Citations to this article as recorded by
The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response Di Ai, Eliel N Arrey, Lauren M Postlewait, Yuan Gao, Xiaoxian Li Histopathology.2025;[Epub] CrossRef
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond Athina Stravodimou, Ioannis A. Voutsadakis Expert Review of Anticancer Therapy.2024; 24(3-4): 117. CrossRef
Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification Miseon Lee, Tae-Kyung Yoo, Byung Joo Chae, Ahwon Lee, Yoon Jin Cha, Jieun Lee, Sung Gwe Ahn, Jun Kang Scientific Reports.2024;[Epub] CrossRef
Evaluating the Clinico-Pathological Relationship Between Stromal Tumor-Infiltrating Lymphocytes and Androgen Receptor Expression Across Molecular Subtypes of Invasive Breast Carcinoma Adil Aziz Khan, Sana Ahuja, Kiruthikasri G., Sufian Zaheer Indian Journal of Surgical Oncology.2024; 15(4): 802. CrossRef
Biomarkers and translational research approaches in breast cancer—an update Angelika M. Starzer, Anna S. Berghoff, Rupert Bartsch memo - Magazine of European Medical Oncology.2023; 16(1): 42. CrossRef
Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy Zhendong Shi, Yingxue Liu, Shichao Zhang, Shuanglong Cai, Xu Liu, Jie Meng, Jin Zhang Discover Oncology.2023;[Epub] CrossRef
Purpose PIK3CA, encoding for subunit p110a of phosphatidylinositol 3 kinase, is frequently mutated in breast cancer. PIK3CAmutation was predictive for pathological complete response (pCR) in human epidermal growth factor 2 positive breast cancer. This study explores the association of PIK3CA mutation and pCR in triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.
Materials and Methods
A total of 92 patients with TNBC derived from a prospectively randomized phase II trial GeparSixto study (NCT01426880). Exon 9 and exon 20 of PIK3CA mutations were evaluated by using classical Sanger method with formalin-fixed paraffin-embedded tumor tissues.
Results
Seven of 90 tumors (7.8%) were detectable with a PIK3CA H1047R mutation. Overall, PIK3CA H1047R mutation was significantly associated with a lower pCR rate (14.3% vs. 56.6%; odds ratio, 0.128; 95% confidence interval [CI], 0.015 to 1.108; p=0.047). In carboplatin- containing treatment patients, H1047R mutation trended to predict a lower pCR rate (20% vs. 62.5%; p=0.146). In a multivariable analysis, H1047R mutation trended to predict a lower pCR rate (hazard ratio, 0.1; 95% CI, 0.01 to 1; p=0.056).
Conclusion
TNBC with a PIK3CA H1047R mutation was less likely to achieve pCR after anthracyclinebased neoadjuvant chemotherapy. Development of H1047R mutant selective inhibitors might be helpful to conquer this subtype of breast cancer.
Citations
Citations to this article as recorded by
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer Lisa Richters, Oleg Gluz, Nana Weber-Lassalle, Matthias Christgen, Heinz Haverkamp, Sherko Kuemmel, Mohamad Kayali, Ronald E. Kates, Eva-Maria Grischke, Janine Altmüller, Helmut Forstbauer, Holger Thiele, Michael Braun, Mathias Warm, Anna Ossowski, Rachel JAMA Network Open.2025; 8(2): e2461639. CrossRef
Comprehensive analysis of HER2 Low Breast Cancer Response to Neoadjuvant Chemotherapy, a Retrospective Cohort Study Jie Lian, Ru Yao, Siyuan Pang, Xinyu Ren, Bo Pan, Yidong Zhou Clinical Breast Cancer.2025;[Epub] CrossRef
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer Brian D. Lehmann, Vandana G. Abramson, E. Claire Dees, Payal D. Shah, Tarah J. Ballinger, Claudine Isaacs, Cesar A. Santa-Maria, Hanbing An, Paula I. Gonzalez-Ericsson, Melinda E. Sanders, Kimberly C. Newsom, Richard G. Abramson, Quanhu Sheng, Chih-Yuan H JAMA Oncology.2024; 10(2): 193. CrossRef
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment Elena Zaikova, Brian Y. C. Cheng, Viviana Cerda, Esther Kong, Daniel Lai, Amy Lum, Cherie Bates, Wendie den Brok, Takako Kono, Sylvie Bourque, Angela Chan, Xioalan Feng, David Fenton, Anagha Gurjal, Nathalie Levasseur, Caroline Lohrisch, Sarah Roberts, Ta npj Breast Cancer.2024;[Epub] CrossRef
Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis Gabriela A. Martínez-Nava, Laura Keren Urbina-Jara, Saúl Lira-Albarrán, Henry L. Gómez, Erika Ruiz-García, María Tereza Nieto-Coronel, Rocio Ortiz-Lopez, Kenia Nadiezhda Martínez Villalba, Mariana Muñoz-Sánchez, Dione Aguilar, Liliana Gómez-Flores-Ramos, Diagnostics.2024; 14(3): 287. CrossRef
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein John M. Ketcham, Stephen J. Harwood, Ruth Aranda, Athenea N. Aloiau, Briana M. Bobek, David M. Briere, Aaron C. Burns, Kersti Caddell Haatveit, Andrew Calinisan, Jeffery Clarine, Adam Elliott, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, Benjamin Jone Journal of Medicinal Chemistry.2024; 67(6): 4936. CrossRef
Prevalence and effect of PIK3CA H1047R somatic mutation among Indian head and neck cancer patients Arjita Ghosh, Anbalagan Moorthy Saudi Journal of Biological Sciences.2024; 31(8): 104029. CrossRef
Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review Ehsan Mehrtabar, Amirreza Khalaji, Mojtaba Pandeh, Aram Farhoudian, Nadia Shafiee, Atefe Shafiee, Fatemeh Ojaghlou, Parinaz Mahdavi, Mehdi Soleymani-Goloujeh Medical Oncology.2024;[Epub] CrossRef
Exploring the Inhibitory Efficacy of Resokaempferol and Tectochrysin on PI3Kα Protein by Combining DFT and Molecular Docking against Wild-Type and H1047R Mutant Forms Cristina Paraschiv, Steluța Gosav, Catalina Mercedes Burlacu, Mirela Praisler Inventions.2024; 9(5): 96. CrossRef
Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis Xingxin Wang, Xuhao Li, Tiantian Dong, Wenyan Yu, Zhixia Jia, Yi Hou, Jiguo Yang, Yuanxiang Liu International Journal of Surgery.2024; 110(12): 7962. CrossRef
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy Zhijun Li, Yiqun Han, Jiayu Wang, Binghe Xu Journal of Personalized Medicine.2023; 13(2): 190. CrossRef
Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review Nadine S. van den Ende, Anh H. Nguyen, Agnes Jager, Marleen Kok, Reno Debets, Carolien H. M. van Deurzen International Journal of Molecular Sciences.2023; 24(3): 2969. CrossRef
A light-up fluorescence platform based DNA: RNA hybrid G-quadruplet for detecting single nucleotide variant of ctDNA and miRNA-21 Gaihua Cao, Keyi Long, Yue Qiu, Lan Peng, Haiyan Han, Yongzhong Wang, Danqun Huo, Changjun Hou Talanta.2023; 257: 124373. CrossRef
Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements Alexandre Bertucci, François Bertucci, Anthony Gonçalves Cancers.2023; 15(5): 1416. CrossRef
Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy, Naoto T. Ueno Biomedicines.2023; 11(3): 735. CrossRef
Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation Bianca Lara Venâncio de Godoy, Marina Gobbe Moschetta-Pinheiro, Luiz Gustavo de Almeida Chuffa, Noam Falbel Pondé, Russel J. Reiter, Jucimara Colombo, Debora Aparecida Pires de Campos Zuccari Life Sciences.2023; 324: 121708. CrossRef
Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions Nicholas Mai, Nour Abuhadra, Komal Jhaveri Clinical Breast Cancer.2023; 23(8): 784. CrossRef
Role of epigenetics variation with focus on DNA methylation in triple-negative breast cancer patients GDeepthi Reddy, V Brahmaiah, BY Kavitha, Jayalatha Nethagani, ElizabethCaroline Palaparthi, RajasekharReddy Lebaka, G Deepika Archives of Medicine and Health Sciences.2023; 11(1): 96. CrossRef
Potential Protective Role of Melatonin in Benign Mammary Cells Reprogrammed by Extracellular Vesicles from Malignant Cells Caroline Procópio de Oliveira, Barbara Maria Frigieri, Heidge Fukumasu, Luiz Gustavo de Almeida Chuffa, Adriana Alonso Novais, Debora Aparecida Pires de Campos Zuccari Biomedicines.2023; 11(10): 2837. CrossRef
Role of Epigenetics Variation with Focus on DNA Methylation in Triple-Negative Breast Cancer Patients G. Deepthi Reddy, V. Brahmaiah, B. Y. Kavitha, Jayalatha Nethagani, Elizabeth Caroline Palaparthi, Rajasekhar Reddy Lebaka, G. Deepika Archives of Medicine and Health Sciences.2023; 11(1): 96. CrossRef
Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature Juan C. Hernandez-Prera, Daryoush Saeed-Vafa, Amin Heidarian, Kathleen Gewandter, Kristen Otto, Bruce M. Wenig Head and Neck Pathology.2022; 16(2): 416. CrossRef
PIK3CA Mutations in Diffuse Gliomas: An Update on Molecular Stratification, Prognosis, Recurrence, and Aggressiveness Cheila Brito, Ana Tomás, Ana Azevedo, Susana Esteves, Manuela Mafra, Lúcia Roque, Marta Pojo Clinical Medicine Insights: Oncology.2022;[Epub] CrossRef
Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer Menghao Dong, Benjie Shan, Xinghua Han, Xiaotian Zhao, Fufeng Wang, Liuqing Zhu, Qiuxiang Ou, Xiaopeng Ma, Yueyin Pan Frontiers in Oncology.2022;[Epub] CrossRef
Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study Tatyana N. Sokolova, Tatyana I. Solov'eva, Svetlana N. Aleksakhina, Marina B. Bolieva, Viktor E. Goldberg, Marianna V. Kibisheva, Konstantin V. Menshikov, Dmitrii V. Ryazanov, Aleksandr V. Shkradyuk, Yana S. Chapko, Anna A. Shchukina, Idris M. Khabr Journal of Modern Oncology.2022; 24(1): 12. CrossRef
PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative Liliana Ascione, Paola Zagami, Eleonora Nicolò, Edoardo Crimini, Giuseppe Curigliano, Carmen Criscitiello Journal of Personalized Medicine.2022; 12(11): 1793. CrossRef
Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions Fokhrul Hossain, Samarpan Majumder, Justin David, Lucio Miele Cancers.2021; 13(15): 3739. CrossRef
Single-nucleotide variant of PIK3CA H1047R gene assay by CRISPR/Cas12a combined with rolling circle amplification Gaihua Cao, Xiaolong Chen, Yuanyi Deng, Fuping Nie, Yin Liu, Guoming Wang, Danqun Huo, Changjun Hou Analytica Chimica Acta.2021; 1182: 338943. CrossRef
Identification of effective natural PIK3CA H1047R inhibitors by computational study Naimeng Liu, Xinhui Wang, Xuan Li, Xiaye Lv, Haoqun Xie, Zhen Guo, Jing Wang, Gaojing Dou, Ye Du, Dong Song Aging.2021; 13(16): 20246. CrossRef
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment Hua Sun, Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl, Sherri R. Davies, Matthew H. Bailey, Tina M. Primeau, Jeremy Hoog, Jacqueline L. Mudd, Dennis A. Dean, Rajesh Patidar, Li Chen, Matthew A. Wyczalkowski, Reyka G. Jayasinghe, Nature Communications.2021;[Epub] CrossRef
Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review Ana Julia Aguiar de Freitas, Rhafaela Lima Causin, Muriele Bertagna Varuzza, Cassio Murilo Trovo Hidalgo Filho, Vinicius Duval da Silva, Cristiano de Pádua Souza, Márcia Maria Chiquitelli Marques Cancers.2021; 13(21): 5477. CrossRef
Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis Wei Peng, Jian-Di Li, Jing-Jing Zeng, Xiao-Ping Zou, Deng Tang, Wei Tang, Min-Hua Rong, Ying Li, Wen-Bin Dai, Zhong-Qing Tang, Zhen-Bo Feng, Gang Chen Cancer Cell International.2020;[Epub] CrossRef
Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease Amal Qattan International Journal of Molecular Sciences.2020; 21(23): 8905. CrossRef